Exact Sciences’ Judge Doyle Square decision is right response to bad timing

There are sounds reasons to believe Exact Sciences’ non-invasive test for colon cancer will one day be a widely-recommended preventive procedure. But there is no doubt the announcement last month that a federal health task force gave the test an initial designation of “alternative test,” just as company officials were wrapping up plans for an ambitious expansion at Judge Doyle Square was about the worst timing possible. Very simply the implications for the company’s financial performance, short term as they might be, made the move downtown too risky. It’s too bad, but company CEO Kevin Conroy’s decision to grow the company at its current UW Research Park location is the right thing to do.